Zynerba Pharma Balance Sheet - Quarterly (NASDAQ:ZYNE)

Add to My Stocks
$11.57 $0.82 (6.62%) ZYNE stock closing price Jun 22, 2018 (Closing)

A thorough fundamental analysis involves using data from Zynerba Pharma balance sheet, apart from other financial statements, to value the business. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Zynerba Pharma stock analysis, and provides insights into the firm's financial performance. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Zynerba Pharma balance sheet as at the end of 2018 Q1 indicates an asset turnover ratio of 0 and debt to equity ratio of 0. Also check Zynerba Pharma revenue and Zynerba Pharma operating cash flow for the same period.

View and download Zynerba Pharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.78M1.73M3.01M2.3M2M1.83M1.46M1.76M1.35M1.9M
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets1.11M--2.45M1.14M-----
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable4.6M3.35M3.11M2.02M-1.84M1.69M2.68M--
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses4.13M3.91M4.47M5M5.11M4.28M2.88M1.51M1.09M2.27M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus140.6M138.91M134.48M132.76M130.97M75.54M69.94M63.85M63.04M62.27M
Retained Earnings-90.28M-77.98M-69.86M-61.55M-53.22M-45.96M-39.07M-33.09M-26.86M-22.58M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity50.33M60.94M64.64M71.22M77.76M29.58M30.88M30.77M36.18M39.7M
Total Liabilities & Shareholders Equity59.9M69.05M73.06M79.09M84.7M36.55M36.29M35.8M39.1M43.64M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Zynerba Pharma stock price, and Zynerba Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Zynerba Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: ZYNE total assets, which was at $59.9M for 2018 Q1 is a balance sheet item representing value of what Zynerba Pharma owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Zynerba Pharma is $9.57M. Shareholders equity comes under liabilities as it is money the company owes the holders of ZYNE stock.

Zynerba Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover